JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB269253

Anti-PD-L1 antibody [MIH5]

5

(1 Review)

|

(2 Publications)

Rat Monoclonal PD-L1 antibody. Suitable for Flow Cyt, WB and reacts with Mouse samples. Cited in 2 publications.

View Alternative Names

CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1

2 Images
Flow Cytometry - Anti-PD-L1 antibody [MIH5] (AB269253)
  • Flow Cyt

Supplier Data

Flow Cytometry - Anti-PD-L1 antibody [MIH5] (AB269253)

Flow cytometry analysis of C57Bl/6 mouse splenocytes stained for PD-L1 with an anti-Mouse CD3e APC and 0.25 μg of Rat IgG2a K Isotype Control Purified (left) or 0.25 μg of ab269253 (right) followed by an anti-Rat IgG Biotin and Streptavidin PE.

Total viable cells were used for analysis.

Western blot - Anti-PD-L1 antibody [MIH5] (AB269253)
  • WB

Supplier Data

Western blot - Anti-PD-L1 antibody [MIH5] (AB269253)

A 25 kDa band (*) corresponding to IgG was also observed in these tissues.

NuPAGE™ 10% Bis-Tris Protein Gel

All lanes:

Western blot - Anti-PD-L1 antibody [MIH5] (ab269253) at 1/500 dilution

Lane 1:

Mouse heart tissue lysate at 30 µg

Lane 2:

Mouse testis tissue lysate at 30 µg

Secondary

All lanes:

F(<a href='/en-us/products/unavailable/hif1-beta-antibody-chip-grade-ab2'>ab2</a>-Rabbit anti-Rat IgG (H+L Secondary Antibody, HRP at 1/4000 dilution

Predicted band size: 33 kDa

false

Key facts

Host species

Rat

Clonality

Monoclonal

Clone number

MIH5

Isotype

IgG2a

Light chain type

lambda

Carrier free

No

Reacts with

Mouse

Applications

WB, Flow Cyt

applications

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p>Use 0.25 μg/test.</p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500", "WB-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification
Purification notes
Greater than 90%, as determined by SDS-PAGE.
Storage buffer
pH: 7.2 Preservative: 0.09% Sodium azide Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
See full target information CD274

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Environmental toxicology 39:2980-2992 PubMed38317501

2024

Circ_0000877 accelerates proliferation and immune escape of non-small cell lung cancer cells by regulating microRNA-637/E2F2 axis.

Applications

Unspecified application

Species

Unspecified reactive species

Ting'an Chen,Zhengdong Li,Junzhu Chen,Zhe Xu

American journal of cancer research 12:5286-5299 PubMed36504904

2022

Chronic stress promotes tumor immune evasion via the suppression of MHC-I expression and the upregulation of PD-L1.

Applications

Unspecified application

Species

Unspecified reactive species

Yuzhu Chen,Yazhi Qian,Wei Huang,Yi Zhang,Mo Wu,Yinlong Cheng,Nan Yang,Yanyong Liu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com